No Data
No Data
TD Cowen Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)
Annexon Presents Phase 2 Vision Preservation Data With ANX007 in Dry AMD
Annexon To Present New Phase 2 ARCHER Data For ANX007 In Dry AMD Patients With Less Advanced GA At The American Academy Of Ophthalmology 2024 Meeting
Here's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn Situation
Annexon Added to Q4 2024 Tactical Ideas List at Wells Fargo
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14
No Data
No Data